Saturday 17 October 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
255.55
2.27
+0.90%
Follow JNJ
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
30.68 | 29.43 | 28.26 | 18.73 |
+8 more quarters Free account |
P/S ratio |
6.42 | 6.24 | 6.11 | 5.29 | |
P/FCF ratio |
28.05 | 26.91 | 32.26 | 24.40 | |
P/Operating CF |
73.97 | 70.96 | 234.20 | 68.16 | |
P/B ratio |
7.50 | 7.20 | 7.25 | 6.11 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.58 | 6.41 | 6.27 | 5.49 | |
EV/EBITDA |
18.75 | 18.01 | 17.43 | 12.29 | |
EV/Operating CF |
23.69 | 22.75 | 26.42 | 21.10 | |
EV/FCF |
28.78 | 27.64 | 33.10 | 25.35 | |
Quick Ratio |
— | 0.73 | 0.69 | 0.69 | |
Current Ratio |
— | 1.09 | 1.03 | 1.03 | |
Net Debt/EBITDA |
— | 1.80 | 1.82 | 2.60 | |
Debt/Assets |
— | 18.57% | 18.68% | 19.80% | |
Debt/Equity |
— | 0.44 | 0.46 | 0.48 | |
Asset Turnover |
0.00 | 0.50 | 0.49 | 0.50 | |
Operating CF/Net income |
0.00 | 1.56 | 0.48 | 1.43 | |
Capex/Depreciation |
— | (0.64) | (0.51) | (0.76) | |
Interest Coverage |
— | 25.79 | 23.86 | 25.31 | |
Research and Development Expense of Revenue |
18.32% | 14.43% | 14.66% | 17.31% | |
Selling, General and Administrative Expense of Revenue |
24.75% | 25.41% | 25.08% | 27.49% | |
Intangible Assets out of Total Assets |
— | 0.48 | 0.49 | 0.50 | |
Share Based Compensation of Revenue |
0.00% | 1.81% | 1.25% | 1.26% | |
Graham Net Nets |
(0.09) | (0.09) | (0.10) | (0.12) | |
Graham Number |
— | 82.79 | 80.99 | 91.77 | |
Earnings Yield |
3.26% | 3.40% | 3.54% | 5.34% | |
Free Cash Flow Yield |
3.57% | 3.72% | 3.10% | 4.10% | |
Revenue per Share |
0.00 | 10.51 | 9.99 | 10.20 | |
Operating CF per Share |
— | 3.58 | 1.04 | 3.04 | |
Capex per Share |
— | (0.52) | (0.42) | (0.63) | |
Free Cash Flow per Share |
— | 3.06 | 0.62 | 2.40 | |
Cash per Share |
— | 8.62 | 9.15 | 8.35 | |
Shareholders Equity per Share |
— | 35.30 | 33.71 | 33.87 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
— | 35.30 | 33.71 | 33.87 | |
Free Cash Flow |
— | 7,358.00 | 1,494.00 | 5,784.00 | |
Working Capital |
— | 4,879.00 | 1,457.00 | 1,498.00 | |
Capital Expenditures |
— | (1,258.00) | (1,020.00) | (1,525.00) | |
Net Current Asset Value |
— | (56,316.00) | (60,535.00) | (62,042.00) | |
EV/EBIT |
34.13 | 23.16 | 22.44 | 14.95 | |
Capex to Sales |
0.00 | 0.05 | 0.04 | 0.06 | |
Price to Operating Income |
35.93 | 24.27 | 23.61 | 15.29 | |
| Other line items | |||||
Average Receivables |
— | 18,446.00 | 16,870.50 | 16,010.00 | |
Average Payables |
— | 9,343.50 | 10,002.50 | 11,151.00 | |
Average Inventory |
— | 14,278.00 | 13,621.00 | 13,317.50 | |
Average Assets |
— | 197,225.00 | 197,282.50 | 189,657.00 | |
Average Common Equity |
— | 81,722.00 | 79,647.50 | 76,517.00 |
Columns are period end dates · fundamentals updated 14 Oct 2026